Cara Total Assets from 2010 to 2024

CARA Stock

USD 0.31 0.01 3.33%

Cara Therapeutic's Total Assets are increasing over the years with slightly volatile fluctuation. Overall, Total Assets are expected to go to about 136.4 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2011-12-31

Previous Quarter

72.5 M

Current Value

51.3 M

Quarterly Volatility

74.9 M

Yuan Drop

Covid

Check Cara Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cara Therapeutic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 246.1 K, Interest Expense of 1 M or Selling General Administrative of 15.7 M, as well as many indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or PTB Ratio of 0.67. Cara financial statements analysis is a perfect complement when working with Cara Therapeutic Valuation or Volatility modules.

Check out the analysis of Cara Therapeutic Correlation against competitors.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

Latest Cara Therapeutic's Total Assets Growth Pattern

Below is the plot of the Total Assets of Cara Therapeutic over the last few years. Total assets refers to the total amount of Cara Therapeutic assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cara Therapeutic books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Cara Therapeutic's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cara Therapeutic's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 125.84 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Cara Total Assets Regression Statistics

	Arithmetic Mean	117,275,515
	Geometric Mean	69,307,594
	Coefficient Of Variation	77.65
	Mean Deviation	75,406,816
	Median	110,897,000
	Standard Deviation	91,062,166
	Sample Variance	8292.3T
	Range	265.6M
	R-Value	0.77
	Mean Square Error	3642.5T
	R-Squared	0.59
	Significance	0.0008
	Slope	15,668,447
	Total Sum of Squares	116092.5T

Cara Total Assets History

	2024	136.4 M
	2023	125.8 M
	2022	182.2 M
	2021	247.1 M
	2020	271.2 M
	2019	233 M
	2018	190.8 M

Other Fundumenentals of Cara Therapeutic

Intangibles To Total Assets

Cara Therapeutic Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Deferred Long Term Liab	Capital Surpluse	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.98	-0.28	-0.69	0.6	0.54	0.94	0.5	0.98	0.59	0.9	-0.77	0.69	0.95	0.77	0.79	0.8	0.87	0.61	0.67
Total Stockholder Equity	0.98		-0.31	-0.6	0.49	0.45	0.93	0.35	0.94	0.53	0.83	-0.71	0.63	0.9	0.69	0.7	0.86	0.89	0.69	0.62
Net Debt	-0.28	-0.31		0.19	-0.14	-0.34	-0.08	0.07	-0.36	-0.31	-0.37	0.36	-0.06	-0.15	-0.11	-0.24	-0.26	-0.3	0.02	-0.22
Retained Earnings	-0.69	-0.6	0.19		-0.95	-0.94	-0.59	-0.81	-0.73	-0.85	-0.85	0.75	-0.66	-0.8	-0.76	-0.93	-0.28	-0.65	-0.01	-0.94
Accounts Payable	0.6	0.49	-0.14	-0.95		0.94	0.52	0.85	0.65	0.7	0.78	-0.73	0.7	0.67	0.76	0.83	0.14	0.52	-0.09	0.85
Net Receivables	0.54	0.45	-0.34	-0.94	0.94		0.43	0.78	0.62	0.78	0.74	-0.68	0.61	0.63	0.66	0.82	0.11	0.56	-0.23	0.85
Short Term Investments	0.94	0.93	-0.08	-0.59	0.52	0.43		0.49	0.94	0.4	0.81	-0.74	0.78	0.86	0.78	0.63	0.71	0.78	0.57	0.51
Total Liab	0.5	0.35	0.07	-0.81	0.85	0.78	0.49		0.54	0.48	0.61	-0.61	0.59	0.58	0.61	0.67	-0.01	0.41	-0.18	0.64
Total Current Assets	0.98	0.94	-0.36	-0.73	0.65	0.62	0.94	0.54		0.61	0.94	-0.84	0.78	0.91	0.82	0.79	0.7	0.81	0.46	0.65
Short Term Debt	0.59	0.53	-0.31	-0.85	0.7	0.78	0.4	0.48	0.61		0.75	-0.58	0.44	0.74	0.58	0.9	0.37	0.61	0.08	0.9
Common Stock	0.9	0.83	-0.37	-0.85	0.78	0.74	0.81	0.61	0.94	0.75		-0.89	0.8	0.87	0.89	0.88	0.56	0.69	0.31	0.77
Property Plant Equipment	-0.77	-0.71	0.36	0.75	-0.73	-0.68	-0.74	-0.61	-0.84	-0.58	-0.89		-0.85	-0.71	-0.82	-0.69	-0.34	-0.56	-0.15	-0.62
Current Deferred Revenue	0.69	0.63	-0.06	-0.66	0.7	0.61	0.78	0.59	0.78	0.44	0.8	-0.85		0.62	0.9	0.56	0.24	0.45	0.08	0.48
Net Tangible Assets	0.95	0.9	-0.15	-0.8	0.67	0.63	0.86	0.58	0.91	0.74	0.87	-0.71	0.62		0.72	0.89	0.73	0.86	0.54	0.81
Deferred Long Term Liab	0.77	0.69	-0.11	-0.76	0.76	0.66	0.78	0.61	0.82	0.58	0.89	-0.82	0.9	0.72		0.74	0.42	0.55	0.22	0.59
Capital Surpluse	0.79	0.7	-0.24	-0.93	0.83	0.82	0.63	0.67	0.79	0.9	0.88	-0.69	0.56	0.89	0.74		0.52	0.71	0.25	0.92
Net Invested Capital	0.8	0.86	-0.26	-0.28	0.14	0.11	0.71	-0.01	0.7	0.37	0.56	-0.34	0.24	0.73	0.42	0.52		0.79	0.89	0.39
Net Working Capital	0.87	0.89	-0.3	-0.65	0.52	0.56	0.78	0.41	0.81	0.61	0.69	-0.56	0.45	0.86	0.55	0.71	0.79		0.54	0.72
Long Term Investments	0.61	0.69	0.02	-0.01	-0.09	-0.23	0.57	-0.18	0.46	0.08	0.31	-0.15	0.08	0.54	0.22	0.25	0.89	0.54		0.15
Capital Stock	0.67	0.62	-0.22	-0.94	0.85	0.85	0.51	0.64	0.65	0.9	0.77	-0.62	0.48	0.81	0.59	0.92	0.39	0.72	0.15

Click cells to compare fundamentals

About Cara Therapeutic Financial Statements

Cara Therapeutic stakeholders use historical fundamental indicators, such as Cara Therapeutic's Total Assets, to determine how well the company is positioned to perform in the future. Although Cara Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cara Therapeutic's assets and liabilities are reflected in the revenues and expenses on Cara Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cara Therapeutic. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	125.8 M	136.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:

How To Invest In Cara

Details

Is Cara Stock a good investment?

Details

What is Cara Therapeutic's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Cara Therapeutic Correlation against competitors.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.75)

Revenue Per Share

0.202

Quarterly Revenue Growth

(0.86)

Return On Assets

(0.63)

Return On Equity

(1.84)

The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cara Total Assets from 2010 to 2024

Latest Cara Therapeutic's Total Assets Growth Pattern

Cara Total Assets Regression Statistics

Cara Total Assets History

Other Fundumenentals of Cara Therapeutic

Cara Therapeutic Total Assets component correlations

About Cara Therapeutic Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY